Pharmaceutical - Johnson & Johnson, Mergers & Acquisitions


Popular Filters

Johnson & Johnson offered $4.15 billion for its diagnostics unit

Johnson & Johnson offered $4.15 billion for its diagnostics unit


After days of speculation about divestitures by US health care major Johnson & Johnson, the company last…

Johnson & JohnsonMergers & AcquisitionsPharmaceutical

Johnson & Johnson in deal to buy Aragon Pharma for up to $1 billion


US health care giant Johnson & Johnson (NYSE: JNJ) has reached a definitive agreement to acquire Aragon…

Aragon PharmaceuticalsJohnson & JohnsonMergers & AcquisitionsOncologyPharmaceuticalSeragon Pharmaceuticals

Royalty bid for Elan could be withdrawn; J&J sells 25.4 million Elan shares


Ireland-based hostile takeover target Elan (NYSE: ELN) fell 5.2% to 9.29 euros on June 13, the most in…

ElanJohnson & JohnsonMergers & AcquisitionsPharmaceuticalRoyalty Pharma

News briefs from Alimera on Iluvien and Xencor on Xtend; Galapagos milestone and acquisition


US biopharma company Alimera Sciences (Nasdaq: ALIM) says that the Spanish Agency of Drugs and Medical…

Alimera SciencesBiotechnologyCangenixGalapagosIluvienJanssenJohnson & JohnsonMergers & AcquisitionsOphthalmicsPharmaceuticalRegulationResearchXencorXtend

Bayer's Xarelto gets EU clearance for PE and prevention of DVT; gives up on Schiff acquisition


Following swiftly on similar news from the US Food and Drug Administration, German drug major Bayer (BAYN:…

BayerCardio-vascularEuropeJanssenJohnson & JohnsonMergers & AcquisitionsNorth AmericaPharmaceuticalRegulationSchiff Nutrition InternationalXarelto

Johnson & Johnson to set up innovation centers to accelerate partnering


US health care giant Johnson & Johnson (NYSE: JNJ) yesterday said it plans to establish four regional…

Johnson & JohnsonLicensingMergers & AcquisitionsPharmaceuticalResearch

Janssen buys Germany's CorImmun


US health care giant Johnson & Johnson's (NYSE: JNJ) European subsidiary Janssen-Cilag GmbH yesterday…

Cardio-vascularCorImmun GmbHJanssenJohnson & JohnsonMergers & AcquisitionsPharmaceutical

US regulator puts conditions on Johnson & Johnson's proposed buy of Synthes


The US Federal Trade Commission will require health care giant Johnson & Johnson (NYSE: JNJ) to sell…

Johnson & JohnsonMergers & AcquisitionsNorth AmericaPharmaceuticalRegulationSynthes

J&J's Janssen files Xarelto with FDA for new indication; buys Chinese firm


US health care major Johnson & Johnson's (NYSE: JNJ) subsidiary Janssen Research & Development says it…

Asia-PacificBayerBioseal BiotechBiotechnologyCardio-vascularJanssenJohnson & JohnsonMergers & AcquisitionsNorth AmericaPharmaceuticalRegulationXarelto

EU Commission OKs J&J's buy of Synthes, but with conditions


The European Commission last week cleared under the EU Merger Regulation the proposed $21.3 billion acquisition…

Johnson & JohnsonMergers & AcquisitionsPharmaceuticalSynthes

Synthes acquisition by Johnson & Johnson delayed as EU Commission starts in-depth investigation


The planned $21.3 billion acquisition of orthopedic device maker Synthes (SYST: VX), which is listed…

Johnson & JohnsonMergers & AcquisitionsPharmaceuticalSynthes

Sanofi to top Pfizer as number one for global pharma sales


French drug major Sanofi (Euronext: SAN) is expected to take the top spot amongst the world’s pharmaceuticals…

FinancialGlobalJohnson & JohnsonMarkets & MarketingMerck & CoMergers & AcquisitionsNovartisNovo NordiskPfizerPharmaceuticalSanofiTakeda PharmaceuticalsTeva Pharmaceutical Industries

Merck & Co to bank $175 million on selling its share of consumer JV with Johnson & Johnson


US drug giant Merck & Co (NYSE: MRK) said yesterday that it has sold its 50% interest in the Johnson…

Johnson & JohnsonMcNeilMerck & CoMergers & AcquisitionsNorth AmericaPharmaceutical

Back to top